How AstraZeneca found success in out-licensing, in-licensing and a revamped R&D strategy
A steep patent cliff in 2012 forced the Anglo-Swedish company to rethink its entire operation – and the results have shown the right calls were made
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.